Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil

Full text
Author(s):
Freitas, Carolina Gomes ; Walsh, Michael ; Atallah, Alvaro Nagib
Total Authors: 3
Document type: Journal article
Source: BMC CARDIOVASCULAR DISORDERS; v. 17, JUN 7 2017.
Web of Science Citations: 1
Abstract

Background: Warfarin is a commonly used anticoagulant. Whether a given dose of the different formulations of Brazilian warfarin will result in the same effect on the international normalized ratio (INR) is uncertain. The aim of the WARFA trial is to determine whether the branded and two generic warfarins available in Brazil differ in their effect on the INR. Methods: WARFA is a cross-over RCT comparing three warfarins. The formulations tested are the branded Marevan (R) (Uniao Quimica/Farmoquimica) and two generic warfarin (manufactured respectively by Uniao Quimica Farmaceutica Nacional and Laboratorio Teuto Brasileiro). All of them were manufactured in Brazil, are available in all settings of the Brazilian healthcare system and were purchased from retail drugstores. Eligible participants had atrial fibrillation or flutter, had been using warfarin for at least 2 months with a therapeutic range of 2.0-3.0 and had low variability in INR results during the 1st period of the trial. Our primary outcome, for which we have an equality hypothesis, is the difference between warfarins in the mean absolute difference between two INR results, obtained after three and 4 weeks with each drug. Our secondary outcomes, that will be tested for inequality (except for the mean INR, which will be tested for equality), include the difference in the warfarin dose, and time in therapeutic range. Clinical events and adherence were also recorded and will be reported. Discussion: To our knowledge, WARFA will be the first comparison of the more readily applicable INR results between branded and generic warfarins in Brazil. WARFA is important because warfarins are commonly switched between in the course of a chronic treatment in Brazil. Final results of WARFA are expected in May 2017. Trial registration: ClinicalTrials.gov NCT02017197. Registered 11 December 2013. (AU)

FAPESP's process: 13/22618-6 - Therapeutic equivalence between branded and generic warfarin sodium in atrial fibrillation adult patients in Brazil: crossover randomized clinical trial
Grantee:Álvaro Nagib Atallah
Support Opportunities: Regular Research Grants